Quantum-Si incorporated (QSI): Price and Financial Metrics
GET POWR RATINGS... FREE!
QSI Stock Price Chart Interactive Chart >
QSI Price/Volume Stats
| Current price | $2.22 | 52-week high | $5.42 |
| Prev. close | $2.15 | 52-week low | $1.64 |
| Day low | $2.15 | Volume | 531,727 |
| Day high | $2.25 | Avg. volume | 609,291 |
| 50-day MA | $2.22 | Dividend yield | N/A |
| 200-day MA | $3.03 | Market Cap | 310.40M |
Quantum-Si incorporated (QSI) Company Bio
Quantum-Si incorporated operates first next-generation protein sequencing platform for healthcare industries. Its ecosystem encompasses to decode the molecules of life, including sample preparation, sequencing, and data analysis. The company was incorporated in 2013 and is based in Guilford, Connecticut. Quantum-Si incorporated operates as a subsidiary of 4Catalyzer Corporation.
Latest QSI News From Around the Web
Below are the latest news stories about QUANTUM-SI INC that investors may wish to consider to help them evaluate QSI as an investment opportunity.
Quantum-Si and Biovista Partner to Provide AI-Driven Deep Proteomics Insights from the Platinum™ Next-Generation Protein Sequence Platform OutputGUILFORD, Conn., January 09, 2023--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it entered into a partnership and license agreement with Biovista to provide customers greater proteomic insights beyond their protein sequence output. Biovista leverages AI in multiple formats to analyze massive data repositories and visualize non-obvious networks and associations between proteins, diseases, and drug mechanisms-of |
Quantum-Si and Aviva Systems Biology Partner to Co-Develop Sample Preparation Kits for Protein SequencingGUILFORD, Conn., January 09, 2023--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it entered into a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products with an extensive portfolio of over 20,000 antibodies against more than 15,000 human gene targets. This partnership seeks to co-develop protein enrichment kits to enable deep interrogation of proteins |
Quantum-Si Begins Commercial Shipments of the PlatinumTM Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare ConferenceGUILFORD, Conn., January 09, 2023--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that management will discuss the following business updates at the 41st Annual J.P. Morgan Healthcare Conference. |
Revolutionizing Protein Sequencing: Quantum-Si's Single-Molecule TechnologyIn a previous article, I exposed that Quantum-Si (QSI) has developed a single-molecule protein sequencing. Quantum-Si has made some big waves in the world of proteomics with its innovative single-molecule protein sequencing technology. Their chips and software allow for comprehensive protein analysis, which could have major implications for research and diagnostics. The secret to their success is a specialized semiconductor chip that can accurately identify biological materials at a singl... |
Quantum-Si to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceGUILFORD, Conn., December 22, 2022--Quantum-Si to Participate in the 41st Annual J.P. Morgan Healthcare Conference |
QSI Price Returns
| 1-mo | 21.31% |
| 3-mo | -22.65% |
| 6-mo | -38.33% |
| 1-year | -53.65% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 21.31% |
| 2022 | -76.75% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...